Inhibikase Therapeutics (IKT) Competitors $1.54 +0.01 (+0.65%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$1.54 0.00 (0.00%) As of 10/24/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IKT vs. INBX, ATXS, CYRX, SLDB, ALMS, DRUG, LXEO, RAPT, AUTL, and CGEMShould you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include Inhibrx Biosciences (INBX), Astria Therapeutics (ATXS), CryoPort (CYRX), Solid Biosciences (SLDB), Alumis (ALMS), Bright Minds Biosciences (DRUG), Lexeo Therapeutics (LXEO), Rapt Therapeutics (RAPT), Autolus Therapeutics (AUTL), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry. Inhibikase Therapeutics vs. Its Competitors Inhibrx Biosciences Astria Therapeutics CryoPort Solid Biosciences Alumis Bright Minds Biosciences Lexeo Therapeutics Rapt Therapeutics Autolus Therapeutics Cullinan Therapeutics Inhibrx Biosciences (NASDAQ:INBX) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment. Do institutionals and insiders hold more shares of INBX or IKT? 82.5% of Inhibrx Biosciences shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 17.1% of Inhibrx Biosciences shares are owned by insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media refer more to INBX or IKT? In the previous week, Inhibrx Biosciences had 12 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 13 mentions for Inhibrx Biosciences and 1 mentions for Inhibikase Therapeutics. Inhibrx Biosciences' average media sentiment score of 0.36 beat Inhibikase Therapeutics' score of 0.00 indicating that Inhibrx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Inhibikase Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer INBX or IKT? Inhibikase Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 419.48%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Inhibrx Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibrx Biosciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is INBX or IKT more profitable? Inhibrx Biosciences' return on equity of -137.83% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Inhibrx BiosciencesN/A -137.83% -76.31% Inhibikase Therapeutics N/A -350.63%-201.82% Which has preferable valuation & earnings, INBX or IKT? Inhibrx Biosciences has higher revenue and earnings than Inhibikase Therapeutics. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibrx Biosciences$200K4,147.80$1.69B-$10.58-5.41Inhibikase TherapeuticsN/AN/A-$19.03M-$2.67-0.58 Which has more risk & volatility, INBX or IKT? Inhibrx Biosciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. SummaryInhibrx Biosciences beats Inhibikase Therapeutics on 8 of the 14 factors compared between the two stocks. Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IKT vs. The Competition Export to ExcelMetricInhibikase TherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$114.76M$347.55M$6.23B$22.02BDividend YieldN/AN/A5.71%3.58%P/E Ratio-0.58N/A30.0633.18Price / SalesN/A495.53592.4961.49Price / CashN/A22.4437.0124.54Price / Book0.873.7412.044.66Net Income-$19.03M-$133.30M$3.32B$1.01B7 Day Performance-1.91%1.97%1.89%2.24%1 Month Performance-0.65%3.63%7.68%2.10%1 Year Performance-36.36%0.37%56.01%14.01% Inhibikase Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IKTInhibikase Therapeutics1.3762 of 5 stars$1.54+0.7%$8.00+419.5%-38.9%$114.76MN/A-0.586News CoverageGap UpINBXInhibrx Biosciences2.1335 of 5 stars$34.38+5.9%N/A+272.7%$470.27M$200K-3.25166Trending NewsGap UpATXSAstria Therapeutics1.8781 of 5 stars$8.47+1.9%$29.50+248.3%+6.5%$468.97MN/A-4.2130Analyst ForecastCYRXCryoPort2.9566 of 5 stars$9.40+1.1%$12.56+33.6%+59.6%$465.62M$228.38M7.071,186Analyst ForecastSLDBSolid Biosciences3.0194 of 5 stars$6.01+0.8%$15.00+149.6%+0.5%$464.10M$8.09M-2.15100News CoverageALMSAlumis3.3961 of 5 stars$4.61+3.8%$20.17+337.5%-62.3%$462.05MN/A0.00N/ANews CoveragePositive NewsAnalyst ForecastDRUGBright Minds Biosciences2.4957 of 5 stars$64.97+2.7%$81.00+24.7%+23.6%$445.81MN/A-69.86N/APositive NewsLXEOLexeo Therapeutics2.8385 of 5 stars$8.20-0.5%$17.00+107.3%-6.8%$444.97M$650K-2.5258Trending NewsAnalyst ForecastAnalyst RevisionRAPTRapt Therapeutics3.8385 of 5 stars$26.35-1.6%$24.78-6.0%+108.5%$443.05M$1.53M-1.8680Analyst ForecastAnalyst RevisionAUTLAutolus Therapeutics3.8078 of 5 stars$1.65-0.6%$9.12+452.7%-65.5%$441.80M$10.12M-1.96330Analyst ForecastCGEMCullinan Therapeutics3.6557 of 5 stars$7.83+5.8%$26.00+232.1%-51.1%$437.15MN/A-2.4230Positive NewsAnalyst ForecastInsider TradeGap Up Related Companies and Tools Related Companies INBX Alternatives ATXS Alternatives CYRX Alternatives SLDB Alternatives ALMS Alternatives DRUG Alternatives LXEO Alternatives RAPT Alternatives AUTL Alternatives CGEM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:IKT) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
